Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Non-Acetaminophen Acute Liver Failure
NCT06872372Active, not recruiting
- Sponsor
- Lahore General Hospital
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of acetylcysteine in acute liver failure (ALF) (2 arms), sponsored by Lahore General Hospital. Primary endpoints: Survival Rate at 28 days and Mortality Rate at 28 days. Started Jan 2025; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT06872372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872372.